Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling
Natura Myeku, Catherine L. Clelland, Sheina Emrani, et al.
Nature Medicine (2015) Vol. 22, Iss. 1, pp. 46-53
Open Access | Times Cited: 406

Showing 1-25 of 406 citing articles:

Proteasomal and Autophagic Degradation Systems
Ivan Đikić
Annual Review of Biochemistry (2017) Vol. 86, Iss. 1, pp. 193-224
Open Access | Times Cited: 958
Tau-targeting therapies for Alzheimer disease
Erin E. Congdon, Einar M. Sigurdsson
Nature Reviews Neurology (2018) Vol. 14, Iss. 7, pp. 399-415
Open Access | Times Cited: 915
Roles of tau protein in health and disease
Tong Guo, Wendy Noble, Diane P. Hanger
Acta Neuropathologica (2017) Vol. 133, Iss. 5, pp. 665-704
Open Access | Times Cited: 813
The Logic of the 26S Proteasome
G. Collins, Alfred L. Goldberg
Cell (2017) Vol. 169, Iss. 5, pp. 792-806
Open Access | Times Cited: 783
Hallmarks of neurodegenerative diseases
David M. Wilson, Mark Cookson, Ludo Van Den Bosch, et al.
Cell (2023) Vol. 186, Iss. 4, pp. 693-714
Open Access | Times Cited: 781
Protein misfolding in neurodegenerative diseases: implications and strategies
Patrick Sweeney, Hyunsun Park, Marc Baumann, et al.
Translational Neurodegeneration (2017) Vol. 6, Iss. 1
Open Access | Times Cited: 547
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Barry Boland, Wen H. Yu, Olga Corti, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 9, pp. 660-688
Open Access | Times Cited: 467
mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy
Jinghui Zhao, Bo Zhai, Steven P. Gygi, et al.
Proceedings of the National Academy of Sciences (2015) Vol. 112, Iss. 52, pp. 15790-15797
Open Access | Times Cited: 424
Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
Sarah L. DeVos, Rebecca L. Miller, Kathleen M. Schoch, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 374
Open Access | Times Cited: 420
Regulation of proteasome assembly and activity in health and disease
Adrien Rousseau, Anne Bertolotti
Nature Reviews Molecular Cell Biology (2018) Vol. 19, Iss. 11, pp. 697-712
Open Access | Times Cited: 416
In Situ Structure of Neuronal C9orf72 Poly-GA Aggregates Reveals Proteasome Recruitment
Qiang Guo, Carina Lehmer, Antonio Martínez-Sánchez, et al.
Cell (2018) Vol. 172, Iss. 4, pp. 696-705.e12
Open Access | Times Cited: 374
Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains
Tamta Arakhamia, Christina E. Lee, Yari Carlomagno, et al.
Cell (2020) Vol. 180, Iss. 4, pp. 633-644.e12
Open Access | Times Cited: 344
Glial contributions to neurodegeneration in tauopathies
Cheryl E. G. Leyns, David M. Holtzman
Molecular Neurodegeneration (2017) Vol. 12, Iss. 1
Open Access | Times Cited: 339
The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death
Ido Livneh, Victoria Cohen‐Kaplan, Chen Cohen-Rosenzweig, et al.
Cell Research (2016) Vol. 26, Iss. 8, pp. 869-885
Open Access | Times Cited: 292
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Rik Ossenkoppele, Rik van der Kant, Oskar Hansson
The Lancet Neurology (2022) Vol. 21, Iss. 8, pp. 726-734
Open Access | Times Cited: 279
Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons
Rik van der Kant, Vanessa F. Langness, Cheryl Herrera, et al.
Cell stem cell (2019) Vol. 24, Iss. 3, pp. 363-375.e9
Open Access | Times Cited: 275
Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases
Qiuyang Zheng, Timothy Y. Huang, Lishan Zhang, et al.
Frontiers in Aging Neuroscience (2016) Vol. 8
Open Access | Times Cited: 273
Phosphorylated tau interactome in the human Alzheimer’s disease brain
Eleanor Drummond, Geoffrey Pires, Claire MacMurray, et al.
Brain (2020) Vol. 143, Iss. 9, pp. 2803-2817
Open Access | Times Cited: 260
NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations
Leanne Mortimer, France Moreau, Justin A. MacDonald, et al.
Nature Immunology (2016) Vol. 17, Iss. 10, pp. 1176-1186
Closed Access | Times Cited: 235
Tau-based therapies in neurodegeneration: opportunities and challenges
Chuanzhou Li, Jürgen Götz
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 12, pp. 863-883
Closed Access | Times Cited: 225
Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
Thomas Cope, Timothy Rittman, Robin Borchert, et al.
Brain (2017) Vol. 141, Iss. 2, pp. 550-567
Open Access | Times Cited: 225
cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins
Sudarsanareddy Lokireddy, Nikolay V. Kukushkin, Alfred L. Goldberg
Proceedings of the National Academy of Sciences (2015) Vol. 112, Iss. 52
Open Access | Times Cited: 220
Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration
Tara E. Tracy, Jesús Madero‐Pérez, Danielle L. Swaney, et al.
Cell (2022) Vol. 185, Iss. 4, pp. 712-728.e14
Open Access | Times Cited: 206
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Simin Qi, Jinyun Dong, Zhiyuan Xu, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 205
Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies
Che-Wei Chang, Qiang Shao, Lennart Mucke
Science (2021) Vol. 371, Iss. 6532
Open Access | Times Cited: 189
Page 1 - Next Page

Scroll to top